Schultz: CDRH Too Slow In Getting Out Guidance Docs And Unlikely To Improve
This article was originally published in The Gray Sheet
Executive SummaryThe pace at which FDA's device center puts out guidance documents is not adequate, admits CDRH Director Dan Schultz, but it is unlikely to improve anytime soon, he said
You may also be interested in...
A surge in Chinese applications for clinical trials for coronavirus treatments, and a fall in patient numbers, are complicating recruitment efforts for the most promising drugs, prompting official moves to tighten study rules.